DrugPatentWatch Database Preview
Details for Patent: 8,362,085
» See Plans and Pricing
Which drugs does patent 8,362,085 protect, and when does it expire?
Patent 8,362,085 protects NAMENDA XR and NAMZARIC and is included in two NDAs.
Protection for NAMENDA XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-nine patent family members in nineteen countries.
Summary for Patent: 8,362,085
Title: | Method for administering an NMDA receptor antagonist to a subject |
Abstract: | The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. |
Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV) |
Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
Application Number: | 13/536,525 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,362,085 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 8,362,085
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Forest Labs Llc | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-001 | Jun 21, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Forest Labs Llc | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-002 | Jun 21, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Forest Labs Llc | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-003 | Jun 21, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Forest Labs Llc | NAMENDA XR | memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022525-004 | Jun 21, 2010 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-003 | Jul 18, 2016 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,362,085
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 481096 | Start Trial | |||
Australia | 2005209310 | Start Trial | |||
Australia | 2005215767 | Start Trial | |||
Australia | 2005215775 | Start Trial | |||
Australia | 2005309601 | Start Trial | |||
Australia | 2006244297 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |